Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped up before the market opened on Monday . The stock had previously closed at $25.33, but opened at $26.36. Ascentage Pharma Group International shares last traded at $25.83, with a volume of 1,165 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have commented on AAPG shares. BTIG Research reaffirmed a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target on the stock. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Finally, China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Trading Up 2.0%

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The stock has a fifty day moving average price of $24.06 and a 200-day moving average price of $28.82.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million during the quarter.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International in the third quarter valued at approximately $96,000. ABC Arbitrage SA purchased a new stake in shares of Ascentage Pharma Group International in the third quarter valued at approximately $204,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, UBS Group AG boosted its stake in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.